DE3436819A1 - Arzneimittel mit grf-wirkung - Google Patents
Arzneimittel mit grf-wirkungInfo
- Publication number
- DE3436819A1 DE3436819A1 DE19843436819 DE3436819A DE3436819A1 DE 3436819 A1 DE3436819 A1 DE 3436819A1 DE 19843436819 DE19843436819 DE 19843436819 DE 3436819 A DE3436819 A DE 3436819A DE 3436819 A1 DE3436819 A1 DE 3436819A1
- Authority
- DE
- Germany
- Prior art keywords
- grf
- formula
- compounds
- effect
- medicinal products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000694 effects Effects 0.000 title claims description 8
- 229940126601 medicinal product Drugs 0.000 title description 2
- 101710142969 Somatoliberin Proteins 0.000 claims description 15
- 102100022831 Somatoliberin Human genes 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 208000037824 growth disorder Diseases 0.000 claims description 3
- 102000018997 Growth Hormone Human genes 0.000 description 5
- 108010051696 Growth Hormone Proteins 0.000 description 5
- 239000000122 growth hormone Substances 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 206010000599 Acromegaly Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000005521 carbonamide group Chemical group 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843436819 DE3436819A1 (de) | 1984-10-06 | 1984-10-06 | Arzneimittel mit grf-wirkung |
| EP85112042A EP0177826A3 (de) | 1984-10-06 | 1985-09-23 | Arzneimittel und Diagnostikum mit Wachstumshormon-Releasingfaktor-Wirkung |
| HU853760A HUT40761A (en) | 1984-10-06 | 1985-09-30 | Process for preparing pharmaceutical preparations with growth regulating effect |
| PT81254A PT81254B (de) | 1984-10-06 | 1985-10-04 | Arzneimittel mit grf-wirkung |
| GR852404A GR852404B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1984-10-06 | 1985-10-04 | |
| ES547598A ES8605376A1 (es) | 1984-10-06 | 1985-10-04 | Procedimiento para preparar un medicamento a base de un polipeptido. |
| DK453785A DK453785A (da) | 1984-10-06 | 1985-10-04 | Laegemiddel med grf-virkning |
| AU48332/85A AU581688B2 (en) | 1984-10-06 | 1985-10-04 | Medicaments with GRF activity |
| PH32878A PH21845A (en) | 1984-10-06 | 1985-10-04 | Medicaments with grf activity |
| IL76572A IL76572A0 (en) | 1984-10-06 | 1985-10-04 | Medicaments with grf activity |
| JP60220491A JPS6193126A (ja) | 1984-10-06 | 1985-10-04 | 成長ホルモン放出因子活性を有する医薬 |
| PH34392A PH21830A (en) | 1984-10-06 | 1986-10-20 | Medicaments with grf activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843436819 DE3436819A1 (de) | 1984-10-06 | 1984-10-06 | Arzneimittel mit grf-wirkung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3436819A1 true DE3436819A1 (de) | 1986-04-17 |
Family
ID=6247348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19843436819 Withdrawn DE3436819A1 (de) | 1984-10-06 | 1984-10-06 | Arzneimittel mit grf-wirkung |
Country Status (11)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0657658B2 (ja) * | 1985-04-11 | 1994-08-03 | 住友製薬株式会社 | 徐放性製剤 |
| EP0203555A3 (de) * | 1985-05-31 | 1987-11-25 | Bissendorf Peptide GmbH | Mittel zur Funktionsdiagnose der Hypophyse und zur Therapie von Störungen der Hypophysenfunktionen |
| CA1317222C (en) * | 1986-12-22 | 1993-05-04 | Rodney Kenneth Mcguffey | Increasing endogenous growth hormone |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3327007A1 (de) * | 1983-07-27 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Herstellung von polypeptiden mit einem saeureamid-carboxyterminus |
| AU575843B2 (en) * | 1983-08-10 | 1988-08-11 | The Administrators Of The Tulane Eductional Fund | Growth hormone releasing peptides |
| PT79094B (en) * | 1983-08-29 | 1986-08-14 | Salk Inst For Biological Studi | Grf analogs |
-
1984
- 1984-10-06 DE DE19843436819 patent/DE3436819A1/de not_active Withdrawn
-
1985
- 1985-09-23 EP EP85112042A patent/EP0177826A3/de not_active Withdrawn
- 1985-09-30 HU HU853760A patent/HUT40761A/hu unknown
- 1985-10-04 PT PT81254A patent/PT81254B/pt unknown
- 1985-10-04 PH PH32878A patent/PH21845A/en unknown
- 1985-10-04 IL IL76572A patent/IL76572A0/xx unknown
- 1985-10-04 ES ES547598A patent/ES8605376A1/es not_active Expired
- 1985-10-04 JP JP60220491A patent/JPS6193126A/ja active Pending
- 1985-10-04 GR GR852404A patent/GR852404B/el unknown
- 1985-10-04 AU AU48332/85A patent/AU581688B2/en not_active Ceased
- 1985-10-04 DK DK453785A patent/DK453785A/da not_active Application Discontinuation
-
1986
- 1986-10-20 PH PH34392A patent/PH21830A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK453785D0 (da) | 1985-10-04 |
| PH21830A (en) | 1988-03-17 |
| ES8605376A1 (es) | 1986-03-16 |
| PT81254A (de) | 1985-11-01 |
| AU4833285A (en) | 1986-04-10 |
| PH21845A (en) | 1988-03-17 |
| GR852404B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1986-02-04 |
| DK453785A (da) | 1986-04-07 |
| ES547598A0 (es) | 1986-03-16 |
| EP0177826A2 (de) | 1986-04-16 |
| HUT40761A (en) | 1987-02-27 |
| JPS6193126A (ja) | 1986-05-12 |
| EP0177826A3 (de) | 1988-03-09 |
| AU581688B2 (en) | 1989-03-02 |
| IL76572A0 (en) | 1986-02-28 |
| PT81254B (de) | 1987-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69110101T2 (de) | GIP-Analoge und deren Verwendung. | |
| DE69233188T2 (de) | Hormonanaloge mit mehreren ctp-erweiterungen | |
| DE3852636T2 (de) | Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2). | |
| DE69101187T2 (de) | VIP-Analogen und ihre Verwendung. | |
| DE3887052T2 (de) | Menschliche, Insulin ähnliche Wachstumfaktoren mit reduzierter Bindung zu Serumträgerproteinen und ihre Herstellung in Hefe. | |
| DE69125394T2 (de) | Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth) | |
| DE3787460T2 (de) | Schimärische peptide für die lieferung von neuropeptiden durch die blut-hirn-grenze. | |
| DE69031168T2 (de) | Verwendung von IGF1 oder IGF2 zur Herstellung eines Medikaments für die Behandlung von amyotrophischen Lateralsklerose | |
| DE2415101C2 (de) | Verwendung von EGF (epidemischer Wachstumsfaktor) zur Inhibierung der Sekretion von saurem Magensaft bei Warmblütern | |
| DE69826132T2 (de) | Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption | |
| DE69626034T2 (de) | Zusammensetzung für verbesserung der pankreasfunktion | |
| DE69532436T2 (de) | Einzelkettenformen des clycoprotein-hormon-quartetts | |
| DE19757250A1 (de) | Insulin-like growth factor binding protein und seine Verwendung | |
| DE69426270T2 (de) | Hgh-rh(1-29)nh2 analoge mit antagonistischer aktivität | |
| EP0185210A2 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| CH650678A5 (de) | Pharmazeutisches mittel aus human-insulin und human-proinsulin. | |
| DE69322958T2 (de) | Stabilisiertes somatotropin zur parenteralen verabreichung | |
| CH650679A5 (de) | Gegen diabetes mellitus wirksames pharmazeutisches mittel. | |
| DE69329899T2 (de) | Behandlung von tropikalischer spastischer Paresis mit Peptide T | |
| DE69010294T2 (de) | Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs. | |
| DE3436819A1 (de) | Arzneimittel mit grf-wirkung | |
| DE69221725T2 (de) | Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen | |
| DE69327495T2 (de) | Arzneimittel die Glicentin als aktiven Wirkstoff enthalten | |
| DE69029415T2 (de) | Osteogenische Wachstumfaktoren, die aus sich regenerierendem Knochenmark identifiziert werden | |
| EP0110294B1 (de) | Mittel zur Behandlung der Osteoporose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8130 | Withdrawal |